Stockscreener 앱 받기
6.34
5.37%
-0.36
전일 마감가:
$6.70
열려 있는:
$6.68
하루 거래량:
3.93M
Relative Volume:
0.63
시가총액:
$2.21B
수익:
$143.05M
순이익/손실:
$-145.99M
주가수익비율:
-14.81
EPS:
-0.4282
순현금흐름:
$-134.06M
1주 성능:
-1.25%
1개월 성능:
+11.62%
6개월 성능:
+20.99%
1년 성능:
+168.64%
1일 변동 폭
$6.295
$6.69
1주일 범위
$6.295
$6.795
52주 변동 폭
$2.18
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
명칭
Nuvation Bio Inc
전화
332-208-6102
주소
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
6.34 | 2.32B | 143.05M | -145.99M | -134.06M | -0.4282 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-19 | 개시 | B. Riley Securities | Buy |
| 2025-09-30 | 개시 | Jefferies | Buy |
| 2025-04-23 | 개시 | Citizens JMP | Mkt Outperform |
| 2024-03-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-03-26 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2023-01-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-02 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-05-04 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-04-06 | 개시 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 개시 | BMO Capital Markets | Outperform |
| 2021-03-08 | 개시 | BTIG Research | Buy |
| 2021-03-08 | 개시 | Cowen | Outperform |
| 2021-03-08 | 개시 | Jefferies | Buy |
| 2021-03-08 | 개시 | Wedbush | Outperform |
모두보기
Nuvation Bio Inc 주식(NUVB)의 최신 뉴스
Nuvation Bio Inc (NUVB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nuvation Bio Inc (NUVB) Institutional Confidence - TradingKey
Nuvation Bio Inc (NUVB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nuvation Bio Inc (NUVB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nuvation Bio Inc (NUVB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug - Stocktwits
Nuvation Bio Inc (NUVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NUVB|Nuvation Bio Inc|Price:6.420|Chg%:-0.055 - TradingKey
Nuvation Bio Inc (NUVB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nuvation Bio Inc. (NUVB) Stock Analysis: A Potential 90% Upside In The Biotech Sector - DirectorsTalk Interviews
Nuvation Bio Inc (NUVB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nuvation Bio to report Q2 2026 results on August 6 - scanx.trade
RBC Capital reiterates Nuvation Bio stock rating on pipeline potential - Investing.com India
Nuvation Bio To Report Second Quarter 2026 Financial Results - TradingView
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 - Yahoo Finance
Nuvation Bio's Safusidenib Clinical Program, Ibtrozi Opportunity Create Favorable Setup, RBC Says - Moomoo
RBC Capital reiterates Nuvation Bio stock rating on pipeline potential By Investing.com - Investing.com South Africa
Truist Financial Maintains Nuvation Bio(NUVB.US) With Buy Rating - Moomoo
Nuvation Bio (NUVB) Could Be 48% Undervalued As Safusidenib Data Strengthens Its Case - Sahm
Frontier tech research, news & data - MLQ.ai
JonesTrading Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Nuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock? - Yahoo Finance
Developing Better Drugs, Not Just More Drugs: Q&A with David Hung - Pharmaceutical Executive
symbol__ Stock Quote Price and Forecast - CNN
Nuvation Bio stock jumps on safusidenib trial expansion plans - Investing.com India
Nuvation Bio stock jumps on safusidenib trial expansion plans By Investing.com - Investing.com Nigeria
RBC Capital Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $19 - Moomoo
BUZZ-U.S. STOCKS ON THE MOVE-Yum Brands, AMD, Nuvation Bio - Bitget
NUVB Stock Slides On Financing As Bullish Analysts Double Down - StocksToTrade
Nuvation Bio to advance glioma drug to Phase III trial after positive three-year data - Yahoo
Nuvation Bio reports 51.9% response rate for safusidenib in Phase 2 glioma study - grafa.com
Why Is Nuvation Bio Stock Gaining Monday? - Benzinga
Nuvation Bio posts corporate deck highlighting IBTROZI ROS1+ NSCLC launch, safusidenib IDH1 glioma program - Bitget
Nuvation Bio (NUVB) Corporate presentation Summary - Quartr
Nuvation Bio expands safusidenib program with two new studies By Investing.com - Investing.com Nigeria
Nuvation Bio expands safusidenib program with two new studies - Investing.com
Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma - Investing News Network
NUVB: IBTROZI's global success and a robust pipeline drive growth in high-value oncology markets - TradingView
Form 4 Nuvation Bio Inc For: 17 July By Investing.com - Investing.com South Africa
Nuvation Bio (NUVB) CFO exercises 40,000 share options and boosts holdings - Stock Titan
Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Gros - The National Law Review
How Nuvation Bio Manages its Ongoing Clinical Trials - Pharmaceutical Executive
Goodwin Advises On Nuvation Bio’s $287.5 Million Registered Convertible Senior Notes Offering With Capped Call - Mondaq
The Status of Nuvation Bio’s Pipeline - Pharmaceutical Executive
Nuvation Bio’s Global Strategy - Pharmaceutical Executive
RBC Capital Cuts PT on Nuvation Bio (NUVB) in Q2 Preview - Yahoo Finance
Nuvation Bio Inc (NUVB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Nuvation Bio Inc 주식 (NUVB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Markel Stacy | CHIEF PEOPLE OFFICER |
Jun 23 '26 |
Option Exercise |
1.83 |
125,000 |
229,249 |
157,591 |
| Markel Stacy | CHIEF PEOPLE OFFICER |
Jun 23 '26 |
Sale |
6.03 |
125,000 |
753,188 |
32,591 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER |
Jun 23 '26 |
Option Exercise |
2.93 |
63,000 |
184,590 |
116,000 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER |
Jun 23 '26 |
Sale |
6.02 |
63,000 |
379,191 |
53,000 |
| Sauvage Philippe | Chief Financial Officer |
Jun 23 '26 |
Option Exercise |
2.17 |
47,668 |
103,440 |
60,341 |
| Sauvage Philippe | Chief Financial Officer |
Jun 23 '26 |
Sale |
6.01 |
47,668 |
286,370 |
12,673 |
2.44%
0.02%
자본화:
|
볼륨(24시간):